US-based medical technology company Medtronic has begun the post-market study of the Valiant Navion thoracic stent graft system in patients with thoracic aortic dissection.
The prospective, observational, global, multi-centre, real-world study will evaluate the safety and effectiveness of the system in the treatment of thoracic aortic dissection.
Thoracic aortic dissection is a serious condition, in which the inner layer of the lower aorta is torn, separating the inner and middle layers of the aorta.
The first patient procedure in the DISSECT-N study was performed at Northwell Health in New York by aortic surgery director Derek Brinster.